COVID-19: Test Developers Focus On New Variants
Executive Summary
Researchers discussed ways to ensure COVID-19 diagnostics work for all variants during a recent webinar.
You may also be interested in...
Diagnostics Saves Roche From Q1 Difficulties
In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues.
Coronavirus Variants Spur FDA To Write New Guidance For COVID-19 Test Developers
The US agency’s immediately-in-effect guidance document – released on 22 February – explains how makers of COVID-19 diagnostics can assess whether their tests are impacted by mutations of the virus.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.